文献速递免疫规划传染病防控与疫情报告

JYNNEOS疫苗预防猴痘的估计有效性:美国多辖区病例对照研究,2022年8月19日至2023年3月31日

Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022-March 31, 2023.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2023-05-19

在美国12个辖区开展匹配病例对照研究,纳入309例猴痘病例和608例对照,评估JYNNEOS疫苗对18-49岁男男性行为者和跨性别成人的有效性。调整后疫苗有效性:部分接种(1剂)为75.2%(95%CI=61.2%至84.2%),完整接种(2剂)为85.9%(95%CI=73.8%至92.4%)。JYNNEOS疫苗可有效降低猴痘风险,建议高风险人群按ACIP推荐接种2剂系列。

要点

  • JYNNEOS疫苗完整接种对猴痘的调整后有效性为85.9%(95%CI=73.8%至92.4%)。
  • 部分接种(1剂)调整后有效性为75.2%(95%CI=61.2%至84.2%)。
  • 建议高风险暴露人群按ACIP推荐接种2剂系列,无论接种途径或免疫状态。

核心结论

  • JYNNEOS疫苗可有效降低猴痘风险。
  • 由于1剂与2剂的保护持续时间仍未知,猴痘暴露风险增加者应按ACIP推荐接种2剂系列,无论接种途径或免疫抑制状态。

研究设计与样本

  • 在美国12个辖区(包括9个新发感染计划站点和3个流行病学与实验室能力站点)开展匹配病例对照研究。
  • 研究对象为18-49岁男男性行为者和跨性别成人。
  • 研究期间2022年8月19日至2023年3月31日,共309例病例患者匹配608例对照患者。

主要发现

  • 部分接种(1剂)调整后疫苗有效性为75.2%(95%CI=61.2%至84.2%)。
  • 完整接种(2剂)调整后疫苗有效性为85.9%(95%CI=73.8%至92.4%)。
  • 完整接种按皮下、皮内和异源途径的调整后疫苗有效性分别为88.9%(95%CI=56.0%至97.2%)、80.3%(95%CI=22.9%至95.0%)和86.9%(95%CI=69.1%至94.5%)。
  • 完整接种在免疫抑制参与者中调整后疫苗有效性为70.2%(95%CI=-37.9%至93.6%),在免疫正常参与者中为87.8%(95%CI=57.5%至96.5%)。

关键数值与推荐

  • JYNNEOS疫苗经FDA于2019年批准用于预防天花和猴痘,皮下注射2剂系列(每剂0.5 mL,间隔4周)。
  • FDA于2022年8月9日发布紧急使用授权,允许JYNNEOS皮内注射减剂量2剂系列(每剂0.1 mL,间隔4周)。
  • 疫苗接种可用于已知或推测暴露者的暴露后预防(PEP),以及猴痘风险增加或可能受益者的暴露前预防(PrEP)。

临床怎么用

  • 猴痘暴露风险增加者应按ACIP推荐接种2剂系列,无论接种途径或免疫抑制状态。
  • 原文未报告其他临床实践推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As of March 31, 2023, more than 30,000 monkeypox (mpox) cases had been reported in the United States in an outbreak that has disproportionately affected gay, bisexual, and other men who have sex with men (MSM) and transgender persons (1). JYNNEOS vaccine (Modified Vaccinia Ankara vaccine, Bavarian Nordic) was approved by the Food and Drug Administration (FDA) in 2019 for the prevention of smallpox and mpox via subcutaneous injection as a 2-dose series (0.5 mL per dose, administered 4 weeks apart) (2). To expand vaccine access, an Emergency Use Authorization was issued by FDA on August 9, 2022, for dose-sparing intradermal injection of JYNNEOS as a 2-dose series (0.1 mL per dose, administered 4 weeks apart) (3). Vaccination was available to persons with known or presumed exposure to a person with mpox (postexposure prophylaxis [PEP]), as well as persons at increased risk for mpox or who might benefit from vaccination (preexposure mpox prophylaxis [PrEP]) (4). Because information on JYNNEOS vaccine effectiveness (VE) is limited, a matched case-control study was conducted in 12 U.S. jurisdictions,† including nine Emerging Infections Program sites and three Epidemiology and Laboratory Capacity sites,§ to evaluate VE against mpox among MSM and transgender adults aged 18-49 years. During August 19, 2022-March 31, 2023, a total of 309 case-patients were matched to 608 control patients. Adjusted VE was 75.2% (95% CI = 61.2% to 84.2%) for partial vaccination (1 dose) and 85.9% (95% CI = 73.8% to 92.4%) for full vaccination (2 doses). Adjusted VE for full vaccination by subcutaneous, intradermal, and heterologous routes of administration was 88.9% (95% CI = 56.0% to 97.2%), 80.3% (95% CI = 22.9% to 95.0%), and 86.9% (95% CI = 69.1% to 94.5%), respectively. Adjusted VE for full vaccination among immunocompromised participants was 70.2% (95% CI = -37.9% to 93.6%) and among immunocompetent participants was 87.8% (95% CI = 57.5% to 96.5%). JYNNEOS is effective at reducing the risk for mpox. Because duration of protection of 1 versus 2 doses remains unknown, persons at increased risk for mpox exposure should receive the 2-dose series as recommended by the Advisory Committee on Immunization Practices (ACIP),¶ regardless of administration route or immunocompromise status.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Dalton AF, Diallo AO, Chard AN, et al. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022-March 31, 2023. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37200229. doi:10.15585/mmwr.mm7220a3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。